CATEGORY

September 13, 2023

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA) ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has

Continue Reading

Curia soutient l’essai clinique de phase 1 de Replicate Bioscience sur un vaccin novateur à base d’ARN de nouvelle génération

L’entreprise apporte une substance médicamenteuse fabriquée selon les BPFa afin de permettre la première étude clinique chez un être humain du nouvel ARN auto-répliquant (ARNar) RBI-4000 ALBANY, ÉTAT DE NEW YORK, 13 sept. 2023 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, développement et fabrication en sous-traitance de premier plan,

Continue Reading

Deriv Group to launch Deriv Prime at IFX EXPO Cyprus 2023

Deriv Prime – Liquidity solution provider LIMASSOL, Cyprus, Sept. 13, 2023 (GLOBE NEWSWIRE) — Deriv Group has announced that it will launch its institutional arm, Deriv Prime, at the upcoming IFX Expo in Limassol, Cyprus, from the 19th to the 21st of September 2023. The venture aims to reshape the

Continue Reading

Deriv Group lancera Deriv Prime lors du IFX EXPO Cyprus 2023

Deriv Prime – Les solutions de liquidité LIMASSOL, Chypre, 13 sept. 2023 (GLOBE NEWSWIRE) — Deriv Group a annoncé le lancement prochain de Deriv Prime, sa branche institutionnelle, lors de l’IFX Expo qui se déroulera du 19 au 21 septembre 2023 à Limassol (Chypre). L’entreprise entend redéfinir le cadre d’accès

Continue Reading